Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
Purpose
This is a Phase 3 global, multicenter, 52-week, open-label extension (OLE) rollover study for subjects completing study CN012-0026, CN012-0027 or CN012-0056. Subjects (randomized or non-randomized) who complete the 38-week CN012-0026 study, 14-week CN012-0027 study or 14-week CN012-0056 study will be eligible to enroll in CN012-0028. The primary objective of the study is to assess the long-term safety and tolerability of KarXT in subjects with psychosis associated with Alzheimer's Disease.
Condition
- Psychosis Associated With Alzheimer's Disease
Eligibility
- Eligible Ages
- Between 55 Years and 90 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Must have completed study CN012-0026, CN012-0027 or CN012-0056. - Subject was aged 55 to 90 years, inclusive, at the time of enrollment into the parent CN012-0026, CN012-0027 or CN012-0056 study. - Can understand the nature of the study and protocol requirements and provide a signed informed consent or, if deemed not competent to provide informed consent, the subject's legally acceptable representative must provide informed consent, and the subject must provide informed assent before any study assessments are performed. - At entry into this study, or any time during the study, if a subject needs to relocate from home or residential assisted-living facility to a nursing home facility, the Sponsor/Medical Monitor must approve the subject's participation in the study. - Have an identified or proxy caregiver (spends approximately 10 hours/week with the subject).
Exclusion Criteria
- Significant or severe medical conditions that, in the opinion of the Investigator, could jeopardize the safety of the subject, ability to complete or comply with the study procedures or validity of the study results. - Clinically significant abnormalities, including any finding(s) from the ECG, laboratory tests, physical examination, or vital signs, at the EOT visit of Study CN012-0026, CN012-0027 or CN012-0056 that the Investigator, in consultation with the Medical Monitor, are considered to jeopardize the safety of the subject. - Subjects participating in another investigational drug or device study or planning on participating in another clinical study during the duration of CN012-0028.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- N/A
- Intervention Model
- Single Group Assignment
- Primary Purpose
- Treatment
- Masking
- None (Open Label)
Arm Groups
Arm | Description | Assigned Intervention |
---|---|---|
Experimental KarXT |
Xanomeline and Trospium Chloride Capsules |
|
Recruiting Locations
Anaheim, California 92805-5854
Steven Macina, Site 1104
714-493-7258
Sherman Oaks, California 91403-2131
Maria Seliverstov, Site 1103
818-990-2671
Clermont, Florida 34711-5933
Christopher Galloway, Site 1048
321-500-5252
Cutler Bay, Florida 33189-1230
Suez Oramas Mingo, Site 1138
305-424-8696
Daytona Beach, Florida 32117-5532
David Billmeier, Site 1023
386-304-7070
Doral, Florida 33122-1620
Lucinda Cuervo-Ramos, Site 1164
305-888-0410
Doral, Florida 33172-2638
Beatriz Triana, Site 1045
786-741-2287
Hialeah, Florida 33012-3158
Amnerys Garcia, Site 1155
305-246-0873
Hialeah, Florida 33012-3618
Manuel Fernandez, Site 1107
305-828-3555
Hialeah, Florida 33012-4648
Jorge Betancourt, Site 1120
305-456-7782
Hialeah, Florida 33012
Frank Alvarez, Site 1052
786-577-5977
Hialeah, Florida 33016-1814
Jose Gamez, Site 1140
305-805-0921
Homestead, Florida 33032
Nelson Gonzalez, Site 1049
786-715-2200
Homestead, Florida 33033
Angel Carrasco, Site 1159
305-246-0873
Maitland, Florida 32751-5669
Brandon Lenox, Site 1039
407-670-5833
Miami Gardens, Florida 33056-4000
Marta Fernandez, Site 1126
305-269-7100
Miami Lakes, Florida 33014-5602
Nancy Navarro Gonzalez, Site 1032
305-424-7420
Miami Lakes, Florida 33014-6435
Gonzalo Quesada, Site 1102
305-705-4494
Miami Springs, Florida 33166-5260
Antonio Terrelonge, Site 1026
305-885-8983
Miami, Florida 33122-1335
Emelina Arocha, Site 1021
305-445-5994
Miami, Florida 33122-1721
Yanely Pineiro Puebla, Site 1118
786-218-1733
Miami, Florida 33133-4231
Francisco Ricart, Site 1108
208-346-8900
Miami, Florida 33135-1601
Brian Villa, Site 1125
786-238-7099
Miami, Florida 33135-2968
Yordan Orive Gomez, Site 1236
305-223-2000
Miami, Florida 33135
Emilio Mantero-Atienza, Site 1115
305-330-9977
Miami, Florida 33145-2455
Thierry Jacquemin, Site 1143
305-359-7666
Miami, Florida 33155-4630
Michael Pfeffer, Site 1009
305-643-8400
Miami, Florida 33155-6630
Cesar Guerrero, Site 1113
786-359-4867
Miami, Florida 33165-3947
Pilar Trueba, Site 1129
305-888-0410
Miami, Florida 33165
Carlos Ramirez Calderon, Site 1150
786-801-0912
Miami, Florida 33173
Maria Nualart, Site 1111
305-263-7120
Miami, Florida 33174-2950
Sonia Rente, Site 1109
305-551-8493
Miami, Florida 33175
Christopher Jimenez, Site 1158
786-275-4023
Miami, Florida 33176-1451
Sergio Jaramillo, Site 1235
786-558-4823
Miami, Florida 33176-7947
Leon Ramon, Site 1147
786-600-7005
Miami, Florida 33176
Roberto Hernando, Site 1234
305-892-1035
Miami, Florida 33179-2537
Gretel Trullenque, Site 1105
786-391-1137
Miami, Florida 33184-1412
Jorge Gonzalez, Site 1157
305-392-0244
Miami, Florida 33186-5882
Maria Rodil, Site 1042
786-808-0832
Orlando, Florida 32807
Eric Carbonell, Site 1112
407-440-4493
Ormond Beach, Florida 32174-3101
David McDonald, Site 1204
386-673-2500
Sweetwater, Florida 33182
Delores Macksoud, Site 1133
786-542-0297
Tampa, Florida 33614-2700
Sadaf Bazargan, Site 1124
813-300-3300
Tampa, Florida 33614-2869
Al Robaina, Site 1123
813-931-0128
Tampa, Florida 33629-5837
Jamie Fernandez, Site 1110
813-251-1800
Flowood, Mississippi 39232
Joseph Kwentus, Site 1132
601-420-5810
Toms River, New Jersey 08755
Ashok Patel, Site 1232
732-244-2299
Woodmere, New York 11598-1739
David Steiner, Site 1025
516-239-1800
Cypress, Texas 77429-6070
Harpaul Gill, Site 1106
949-491-0710
Houston, Texas 77074-2085
Nelson Berrios, Site 1004
More Details
- NCT ID
- NCT05980949
- Status
- Recruiting
- Sponsor
- Karuna Therapeutics
Study Contact
BMS Clinical Trials Contact Center www.BMSClinicalTrials.com855-907-3286
Clinical.Trials@bms.com